How to address vulnerabilities in production and delivery of critical medicines in the EU
International Coalition of Medicines Regulatory Authorities and World Health Organization workshop
No link between GLP-1 medicines and suicidal and self-injurious thoughts and actions
The Data Analysis and Real World Interrogation Network seeks ten new data partners in 2024
How new ACT EU platform will enable collaboration on clinical research
Find medicine
What's new
FAQs
Latest news
EMA has published a number of recommendations to address vulnerabilities in the production and delivery of medicines included in the Union list of critical medicines and strengthen their supply chain.
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting.
Report on COVID-19 vaccine strain updates: global regulators agree on timing and data requirements
GLP-1 receptor agonists: available evidence not supporting link with suicidal and self-injurious thoughts and actions
Due to planned system maintenance, several EMA applications will be fully or partially inaccessible from 11 to 17 April.
The European Medicines Agency (EMA) reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on 1 April 2024.
Information for you
Patients and carers
Healthcare professionals
Animal health professionals
Pharmaceutical Industry
Media
